Endocrine Abstracts

Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual health complaint worldwide, affecting 1-in-10 women. It is characterised by a persistent lack of desire for sexual activity and sexual fantasies, causing distress or interpersonal difficulties. Treatment options are limited, however, melanocortin-4 receptor (MC4R) agonists have emerged as a promising therapy for HSDD, through unclear mechanisms. Investigating the pathways involved is crucial for our u...

Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with dysfunctional brain activation in regions governing sexual responses, resulting in a deficiency/absence of sexual desire with marked distress. It affects up to 8% of men with detrimental effects on quality of life, interpersonal relationships and fertility, but so far has no licensed treatment options. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role ...

Introduction: Hypoactive sexual desire disorder (HSDD) is characterized by a persistent deficiency of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty. It is the most prevalent female sexual health problem worldwide, affecting approximately 1 in 10 women, but has limited treatment options despite its substantial health, social, and economic burden. Melanocortin-4 receptor (MC4R) agonists have emerged as a promising therapy fo...

Introduction: Sexual desire is a key component of the sexual response model. Absence or deficiency of sexual desire can lead to marked distress or interpersonal difficulty, termed ‘hypoactive sexual desire disorder’ (HSDD). HSDD is the most common female sexual health complaint worldwide, affecting up to 10% of women. Despite its detrimental impact on psychological well-being and quality of life, treatment options are currently limited. The hormone kisspeptin is a ke...

Hypoactive sexual desire disorder (HSDD) is a persistent lack of sexual desire, causing marked interpersonal distress. It is the most common global female sexual health problem, although the precise pathophysiology remains uncertain. Existing treatment options are limited by their efficacy and side effects. The neuropeptide kisspeptin offers a potential therapeutic target given its emerging role in modulating reproductive behaviour. Using a combination of psychometric, neuroim...

Background: Distressing low sexual desire, termed Hypoactive Sexual Desire Disorder (HSDD), affects 10% of women and 8% of men. The established ‘top-down’ neurofunctional model of HSDD in women suggests that in response to erotic cues, excessive activation of higher-level cognitive brain regions (involved in introspection/self-monitoring) suppresses lower-level sexual brain centres, thereby impeding normal sexual function. By contrast, the neurodysfunction in men wit...

Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with a deficiency of sexual desire with marked distress. It affects up to 8% of men, but has no licensed treatments. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role in modulating reproductive behaviour in animal models and healthy men. However, there are no studies examining its effects in HSDD. To address this, we performed the first clinical study of ki...

Background: The neuropeptide kisspeptin is a key endogenous activator of the reproductive system. Due to its crucial role in modulating reproductive and behavioural processes, there has been accelerating interest in targeting kisspeptin-pathways to treat reproductive and psychosexual disorders. However, contradictory pre-clinical data from animal models suggests that kisspeptin can have an anxiolytic, anxiogenic or have no effects on anxiety. Given the rapid development of kis...

Background: The neuropeptide kisspeptin is a critical endogenous activator of the reproductive system, with escalating clinical interest as a novel therapeutic agent for reproductive and psychosexual disorders. However, conflicting animal data suggest that kisspeptin can have anxiolytic, neutral, or anxiogenic effects. Given the rapid development of kisspeptin-based therapeutics, it is important to clarify kisspeptin’s effects on psychometric measures of anxiety and assoc...